v3.25.1
Insider Trading Arrangements
3 Months Ended
Mar. 31, 2025
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
Our policy governing transactions in our securities by our directors, officers and employees permits our directors, officers and employees to enter into trading plans complying with Rule 10b5-1 under the Exchange Act. The following table describes the written plans for the sale of our securities that were adopted by our executive officers and directors during the quarter ended March 31, 2025. Each of the plans was entered into during an open trading window and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (each a “Trading Plan”).


Name and Title
Action Taken (Date)
Scheduled Start Date of Trading Plan
Scheduled Expiration Date of Trading Plan
Maximum Number of Shares Subject to Trading Plan
Paul Friedman, M.D., Director
Adoption (March 14, 2025)
June 13, 2025
July 22, 2026
206,256
Rebecca Taub, M.D., Senior Scientific and Medical Advisor and Director
Adoption (March 14, 2025)
June 13, 2025
July 22, 2026
76,564
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Paul Friedman [Member]  
Trading Arrangements, by Individual  
Name Paul Friedman, M.D.,
Title Director
Rule 10b5-1 Arrangement Adopted true
Adoption Date Adoption (March 14, 2025)
Expiration Date July 22, 2026
Arrangement Duration 404 days
Aggregate Available 206,256
Rebecca Taub [Member]  
Trading Arrangements, by Individual  
Name Rebecca Taub, M.D.,
Title Senior Scientific and Medical Advisor and Director
Rule 10b5-1 Arrangement Adopted true
Adoption Date Adoption (March 14, 2025)
Expiration Date July 22, 2026
Arrangement Duration 404 days
Aggregate Available 76,564